CSPC Pharmaceutical Receives FDA Approval for Phase I Study of CPO301 in Lung Cancer
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced that it has received approval from...
Cancer
Shanghai Fosun Pharmaceutical Gets NMPA Approval for FCN-338 Phase II Study
China-based Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) has announced receiving approval...
Changzhou Qianhong Bio-pharma Receives NMPA Approval for QHRD107 Phase II AML Study
China-based Changzhou Qianhong Bio-pharma Co., Ltd (SHE: 002550) has announced obtaining approval from the National...
Konruns Pharmaceutical Reports Positive Efficacy Results for KC1036 in Advanced ESCC
Beijing-based Konruns Pharmaceutical Co., Ltd (SHA: 603590) has announced the publication of efficacy study results...
Abbisko Therapeutics Secures Orphan Drug Designation for FGFR4 Inhibitor ABSK012
Shanghai-based biotech Abbisko Therapeutics Co., Ltd (HKG: 2256) has announced that it has received orphan...
HutchMed Completes NDA Submission to US FDA for Frquintinib in Metastatic CRC
Hutchison China Meditech (HutchMed; HKG: 0013, NASDAQ: HCM) has announced the completion of a rolling...
Ablaze Pharma Charts Path for GPC3-Targeted Polypeptide with RayzeBio Partnership
Ablaze Pharma, a Chinese biopharmaceutical company, has announced its development plan for a GPC3-targeted polypeptide...
Shanghai Fosun Pharma Commences Phase III Trial for HER2-Targeted FS-1502
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196), a prominent Chinese pharmaceutical company,...
CStone Pharmaceuticals’ Sugemalimab Study Published in JCO for R/R ENKTL Treatment
CStone Pharmaceuticals (HKG: 2616), a China-based biopharmaceutical company, announced that the Journal of Clinical Oncology...
IceCure Medical Gains NMPA Approval for Cryoablation Technology in China
Israel-based IceCure Medical (NASDAQ: ICCM) has announced that it has obtained regulatory approval from China’s...
ImmVira’s MVR-C5252 Receives NMPA Approval for Glioma Treatment Development
China-based biotechnology company ImmVira has received approval from the National Medical Products Administration (NMPA) for...
Transcenta’s Osemitamab Receives FDA Orphan Drug Designation for Pancreatic Cancer
China-based biotechnology company Transcenta Holdings Ltd (HKG: 6628) has announced that its drug TST001 (osemitamab),...
ImmuneOnco Achieves Full Enrollment in Phase II Study of IMM01 for CMML
ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd has announced the successful completion of patient enrollment in its...
Shenzhen Hepalink’s OncoVent Secures Licensing Deal with Orient EuroPharma for Oregovomab
Shenzhen Hepalink Pharmaceutical Group Co., Ltd (SHE: 002399) has announced that its subsidiary, OncoVent, has...
Kintor Pharmaceutical Realigns Funds from COVID-19 Studies to Other Pipeline Candidates
China-based Kintor Pharmaceutical Ltd (HKG: 9939) has announced a strategic change in the allocation of...
Shanghai Pharmaceuticals’ SPH4336 Earns Orphan Drug Status for Liposarcoma Treatment
Shanghai Pharmaceuticals, a leading pharmaceutical company based in China (HKG: 2607, SHA: 601607), has announced...
Junshi Biosciences and Rxilient Biotech Form JV to Commercialize Tuoyi in Southeast Asia
China-based biopharmaceutical company Junshi Biosciences (HKG: 1877, SHA: 688180) has announced a joint venture (JV)...
CDE Grants Priority Review Status to TQB3454, HLX208, and Infigratinib for Cancer Treatments
The Center for Drug Evaluation (CDE) website has indicated that Chia Tai Tianqing’s TQB3454, Henlius...
Berry Genomics Partners with MGI Tech to Advance Cancer Diagnostics and Screening
Chengdu-based Berry Genomics Co., Ltd has announced a strategic partnership with MGI Tech, a subsidiary...
BJ Bioscience Partners with MSD for Phase I Clinical Trial of BJ-001 and Keytruda
Shanghai-based biotech BJ Bioscience Inc. has announced a clinical trial collaboration and supply agreement with...